Teva, Procognia sign agreement for biopharmaceuticals development

By Elaine Rigoli

Tampa, Fla., Sept. 20 - Teva Pharmaceutical Industries, Ltd. and Procognia (Israel), Ltd. entered into a collaboration agreement covering two biopharmaceuticals, under which Procognia will supply services and provide access to its proprietary glycoanalysis technology to Teva on an exclusive basis, according to a company news release.

Teva, the Jerusalem-based generic pharmaceutical company, will fund the costs of the collaboration and pay certain milestones and royalties to Procognia, an Ashdod, Israel-based biological microarray company. Further financial terms of the agreement were not disclosed.

The agreement is subject to pre-defined achievements relating to the usage of the technology in the development of the biopharmaceuticals.

"We believe that accessing the Procognia technology will provide Teva with a distinct competitive advantage. Glycoanalysis is a complex task in producing biopharmaceuticals. Accessing the technology and skill set from Procognia should significantly benefit both the development and manufacturing processes," Teva vice president Amir Elstein said in the release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.